Researchers at VCU Massey Cancer Center identified a novel, protein-based combination therapy through which tumor resistance can be overcome to more effectively treat colorectal cancer.
Researchers at Roswell Park Comprehensive Cancer Center found that mitochondrial unfolded protein response—a unique longevity function of mitochondria—could be a target for the treatment and management of metastatic, resistant, or recurrent prostate cancer.
Researchers at the American Cancer Society found that parental cancer is associated with a greater likelihood of family-level food insecurity, financial worry about housing costs and other monthly bills, and transportation barriers to medical care for children in the United States.
Researchers at ACS showed that the mortality risk from cardiovascular disease differs considerably among cancer survivors by race/ethnicity and cancer types.
In a study of more than 1,500 patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning than those who did not take everolimus. Improvement was seen primarily in patients with very high-risk disease, while patients with intermediate high-risk disease saw no improvement in recurrence-free survival.
Data from the phase II NP30179 expansion study demonstrated that, after a median follow-up of more than 12 months, fixed-duration glofitamab—an investigational CD20xCD3 T cell-engaging bispecific antibody—induced durable complete responses in patients with relapsed or refractory diffuse large B-cell lymphoma who had received a median of three prior therapies.
Preclinical data from a study conducted by Enlivex Therapeutics in collaboration with Yale Cancer Center showed substantial and statistically significant improvements in survival benefit, survival duration, and tumor burden reduction in ovarian cancer when Allocetra was combined with an anti-PD1 checkpoint inhibitor.
Positive updated clinical research highlights the therapeutic potential of CLN-081 in patients with epidermal growth factor receptor exon 20 insertion mutation positive non-small cell lung cancer.
Data from pivotal trials of sugemalimab, a PD-L1 inhibitor, and aumolertinib, a third-generation EGFR-tyrosine kinase inhibitor, demonstrated the potential clinical benefit of these investigational medicines in non-small cell lung cancer and of sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma.
Several studies sponsored by Invitae underscore the importance of genetic testing for improving cancer outcomes, according to the company. These data will be presented at the 2022 ASCO annual meeting.
